Skip directly to page options Skip directly to A-Z link
Volume 26, Number 12—December 2020
Research

Small Particle Aerosol Exposure of African Green Monkeys to MERS-CoV as a Model for Highly Pathogenic Coronavirus Infection

Allison Totura1, Virginia Livingston, Ondraya Frick, David Dyer, Donald Nichols, and Aysegul NalcaComments to Author 
Author affiliation: Author affiliation: US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA

Main Article

Figure 3

Detection of MERS-CoV viral loads in throat swabs and serum from African green monkeys (AGMs). A, B) Infectious MERS-CoV was titrated on Vero cells from throat swab samples (A) and serum samples (B) collected at indicated days after MERS-CoV aerosol exposure of AGMs. C) PRNT50 titers were assessed for AGM serum samples collected at 28 days postinfection. Plaque assays and PRNT50 assays were completed for each sample in triplicate. Differences between groups were evaluated by using 1-way analysis of variance (Tukey’s multiple comparison test; *p<0.05, **p<0.01, ***p<0.001). MERS-CoV, Middle East respiratory syndrome coronavirus; ND, not detected; NS, not significant; PRNT50, 50% reduction plaque reduction neutralization test.

Figure 3. Detection of MERS-CoV viral loads in throat swabs and serum from African green monkeys (AGMs). A, B) Infectious MERS-CoV was titrated on Vero cells from throat swab samples (A) and serum samples (B) collected at indicated days after MERS-CoV aerosol exposure of AGMs. C) PRNT50 titers were assessed for AGM serum samples collected at 28 days postinfection. Plaque assays and PRNT50 assays were completed for each sample in triplicate. Differences between groups were evaluated by using 1-way analysis of variance (Tukey’s multiple comparison test; *p<0.05, **p<0.01, ***p<0.001). MERS-CoV, Middle East respiratory syndrome coronavirus; ND, not detected; NS, not significant; PRNT50, 50% reduction plaque reduction neutralization test.

Download

Main Article

1Current affiliation: US Department of Health and Human Services Biomedical Advanced Research and Development Authority, Washington, DC, USA

Page created: July 22, 2020
Page updated: November 19, 2020
Page reviewed: November 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external